RNAZ Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

-56.000

-90.68%

-8.680

-99.97%

-9.240

-93.75%

Estimates Revision

The market is revising No Change the revenue expectations for TransCode Therapeutics, Inc. (RNAZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.28%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-22.28%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Transcode Therapeutics Inc (RNAZ.O) is -6.80, compared to its 5-year average forward P/E of -2.05. For a more detailed relative valuation and DCF analysis to assess Transcode Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.05

Current PE

-6.80

Overvalued PE

0.55

Undervalued PE

-4.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.57

Current PS

0.00

Overvalued PS

35.56

Undervalued PS

-12.42

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RNAZ News & Events

Events Timeline

No data

News

9.0

12-12NASDAQ.COM

TransCode's TTX-MC138 Set to Begin Phase 2a Trial Within Quantum Leap PRE-I-SPY Initiative

9.0

12-11Newsfilter

TransCode Partners with Quantum Leap for TTX-MC138 Phase 2a Clinical Trial

5.0

11-17PRnewswire

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

People Also Watch

Frequently Asked Questions

What is Transcode Therapeutics Inc (RNAZ) stock price today?

The current price of RNAZ is 9.07 USD — it has decreased -4.63 % in the last trading day.

What is Transcode Therapeutics Inc (RNAZ)'s business?

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

What is the price predicton of RNAZ Stock?

Wall Street analysts forecast RNAZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAZ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Transcode Therapeutics Inc (RNAZ)'s revenue for the last quarter?

Transcode Therapeutics Inc revenue for the last quarter amounts to -4.54M USD, increased 110.78 % YoY.

What is Transcode Therapeutics Inc (RNAZ)'s earnings per share (EPS) for the last quarter?

Transcode Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Transcode Therapeutics Inc (RNAZ)'s fundamentals?

How many employees does Transcode Therapeutics Inc (RNAZ). have?

Transcode Therapeutics Inc (RNAZ) has 7 emplpoyees as of December 16 2025.

What is Transcode Therapeutics Inc (RNAZ) market cap?

Today RNAZ has the market capitalization of 8.32M USD.